People: ACADIA Pharmaceuticals Inc. (ACAD.O)
ACAD.O on Consolidated Issue listed on NASDAQ Global Market
1.30USD
9 Feb 2010
1.30USD
9 Feb 2010
Price Change (% chg)
$0.03 (+2.36%)
$0.03 (+2.36%)
Prev Close
$1.30
$1.30
Open
--
--
Day's High
$1.32
$1.32
Day's Low
$1.25
$1.25
Volume
383,078
383,078
Avg. Vol
673,609
673,609
52-wk High
$6.60
$6.60
52-wk Low
$0.75
$0.75
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Iversen, Leslie | 71 | 2000 | Chairman of the Board |
| Hacksell, Uli | 58 | 2000 | Chief Executive Officer, Director |
| Aasen, Thomas | 48 | 1998 | Chief Financial Officer, Vice President, Secretary, Treasurer |
| Mills, Roger | 51 | 2006 | Executive Vice President - Development |
| Kaplan, Lester | 58 | 1997 | Director |
| Rasmussen, Torsten | 64 | 1998 | Director |
| Walton, Alan | 73 | 2003 | Director |
| Gray, Mary | 56 | 2005 | Director |
| Borer, Michael | 50 | 2005 | Director |
| Brege, Laura | 51 | 2008 | Director |
Biographies
| Name | Description |
|---|---|
| Iversen, Leslie | Dr. Leslie L. Iversen has been the Chairman of the Board of ACADIA Pharmaceuticals, Inc since December 2000. He has served as a director since 1998. He also was a founding member of Scientific Advisory Board. Dr. Iversen is currently a Professor of Pharmacology at University of Oxford, England, where he has taught since 1995. He was previously a Professor of Pharmacology at King’s College, London where he was Director of the Wolfson Centre for Age Related Diseases from 1999 until 2004. Dr. Iversen is internationally recognized for his fundamental contributions to the understanding of neurotransmission. Dr. Iversen served as Vice President of Neuroscience Research, Merck Research Laboratories and Director of the Neuroscience Research Center of Merck Research Laboratories in the UK. He was formerly Director of the Medical Research Council Neurochemical Pharmacology Unit in Cambridge. More recently, Dr. Iversen founded and serves as a director of Panos Therapeutics Ltd. Dr. Iversen is the recipient of numerous awards, including Fellow of the Royal Society of London and Foreign Associate Member of the National Academy of Sciences in the United States. Dr. Iversen received a Ph.D. and B.A. from the University of Cambridge. |
| Hacksell, Uli | Dr. Uli Hacksell has served as Chief Executive Officer since September 2000 and as a Director of ACADIA Pharmaceuticals, Inc since October 2000. From February 1999 to September 2000, he served as Executive Vice President of Drug Discovery. From August 1991 to February 1999, Dr. Hacksell held various senior executive positions at Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology as well as President of Astra Draco, one of Astra’s largest research and development subsidiaries, where he directed an organization of more than 1,100 employees. From August 1991 to May 1994, he served as Vice President of CNS Preclinical R&D at Astra Arcus, another subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. He currently serves as a director, and chairman of the board, of Action Pharma A/S, a privately held company in Denmark, and serves on the board of directors of SLS Invest AB. Dr. Hacksell received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University. |
| Aasen, Thomas | Mr. Thomas H. Aasen has served as Vice President, Chief Financial Officer, Treasurer and Secretary of ACADIA Pharmaceuticals, Inc since April 1998. Prior to joining the company, Mr. Aasen held financial management positions at several publically traded life sciences companies, including Senior Director of Finance and Administration at Axys Pharmaceuticals, formerly called Sequana Therapeutics, Director of Finance at Genta, Inc., and Director of Accounting at Gen-Probe, Inc. Earlier in his career, Mr. Aasen held various positions in public accounting at KPMG Peat Marwick, including Audit Manager. He has over 25 years of professional finance and accounting experience focused primarily on the life sciences industry. Mr. Aasen received a B.S. degree with honors from San Diego State University and is a Certified Public Accountant. |
| Mills, Roger | Dr. Roger M. Mills has served as Executive Vice President, Development of ACADIA Pharmaceuticals, Inc since June 2006. Prior to joining the company, Dr. Mills held the position of Vice President, Development at Pfizer Global R&D, a division of Pfizer Inc., for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer campus in La Jolla, California, and played a key role in the development of Sutent®, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead Sciences, where he served as project leader in the development of Tamiflu®, a top treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular Marketing. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London. |
| Kaplan, Lester | Dr. Lester J. Kaplan has served as a Director of ACADIA Pharmaceuticals, Inc since November 1997. Dr. Kaplan was Executive Vice President and President, Research and Development, at Allergan, Inc. from November 2003 to April 2004. Dr. Kaplan joined Allergan in 1983 and, prior to being appointed to Executive Vice President, was Corporate Vice President, Research and Development and Global BOTOX from June 1998 to November 2003. Dr. Kaplan was elected to Allergan’s board of directors in 1994 and served in that capacity until April 2004. Dr. Kaplan is Executive Chairman of the Board of Aciex Inc., and a member of the Board of The National Neurovision Research Institute. He is a venture partner with Bay City Capital and serves on its Scientific Advisory Board. Dr. Kaplan received a M.S. and Ph.D. in organic chemistry from the University of California, Los Angeles. |
| Rasmussen, Torsten | Mr. Torsten Rasmussen has served as a Director of ACADIA Pharmaceuticals, Inc since April 1998. Mr. Rasmussen has been President and Chief Executive Officer of Morgan Management ApS, a management advisory and consulting company, since 1997. Prior to founding Morgan Management ApS in 1997, Mr. Rasmussen had held the position of Executive Vice President, Operations at the LEGO Group (LEGO A/S) in Denmark, since 1981. He currently serves as a board member in the capacity of chairman, deputy chairman or ordinary board member of a number of Danish companies of which the following are quoted on the Danish Stock Exchange: Coloplast A/S, TK Development A/S, Vestas Wind Systems A/S and A/S Det Oestasiatiske Kompagni. Mr. Rasmussen holds an M.B.A. from IMD in Lausanne, Switzerland. |
| Walton, Alan | Dr. Alan G. Walton has served as a Director of ACADIA Pharmaceuticals, Inc since March 2003. Dr. Walton joined Oxford Partners as a General Partner in 1987. In 1991, he founded Oxford Bioscience Partners and he is currently Senior Partner and Chairman of Oxford Bioscience Corporation. Previously, he was President and CEO of University Genetics Co., a public biotechnology company involved in technology transfer and seed investments in university-related projects. Prior to University Genetics, he taught at several institutions including Harvard Medical School, Indiana University and Case Western Reserve where he was Professor of Macromolecular Science and Director of the Laboratory for Biological Macromolecules. Dr. Walton serves on the Boards of Alexandria Real Estate Equities and Advanced Cell Technology. He is also on the Board of Research!America, a philanthropic organization. Dr. Walton was a founder of Human Genome Sciences and GeneLogic and is the Founding Chairman of the Biotechnology Venture Investors Group. Dr. Walton holds a Ph.D. in chemistry and a D.Sc. in biological chemistry from Nottingham University in England and in 2005 received an honorary LLD degree for his lifetime achievement in life sciences from Nottingham University. Dr. Walton has also been awarded an Adjunct Professorship from Case Western Reserve University. |
| Gray, Mary | Dr. Mary Ann Gray has served as a Director of ACADIA Pharmaceuticals, Inc since April 2005. Currently, Dr. Gray is President of Gray Strategic Advisors, LLC, a company which she started in 2003. Dr. Gray also serves on the boards of directors of Dyax Corp., Telik, Inc. and GTC Biotherapeutics, Inc. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read and Kidder Peabody for an aggregate of nine years. Dr. Gray holds a Ph.D. degree in pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer. |
| Borer, Michael | Mr. Michael T. Borer has served as a Director of ACADIA Pharmaceuticals, Inc since September 2005. Mr. Borer served as Chief Executive Officer and President of Xcel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system, until the sale of the company to Valeant Pharmaceuticals International in early 2005. Prior to founding Xcel in early 2001, Mr. Borer served as Senior Vice President and Chief Financial Officer of Dura Pharmaceuticals, Inc. and held other management positions there from 1994 through 2000. Prior to Dura, Mr. Borer spent 12 years in public accounting with Deloitte & Touche in its audit services group. He holds a bachelor’s degree in accounting from San Diego State University. |
| Brege, Laura | Ms. Laura A. Brege is Director of ACADIA Pharmaceuticals, Inc since May 2008. Ms. Brege is Executive Vice President and Chief Operating Officer of Onyx Pharmaceuticals, Inc. where she is responsible for sales and marketing, medical affairs, legal, business development, and compliance functions. She joined Onyx in June 2006 as Executive Vice President and Chief Business Officer and was promoted to her current position in October 2007. Before joining Onyx, Ms. Brege was a general partner at Red Rock Management, a venture capital firm. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an Master of Business Administration from the University of Chicago. Ms. Brege also serves on the boards of Angiotech Pharmaceuticals, Inc. and The Ohio University Foundation. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Iversen, Leslie | -- |
| Hacksell, Uli | 751,900 |
| Aasen, Thomas | 435,111 |
| Mills, Roger | 567,894 |
| Kaplan, Lester | -- |
| Rasmussen, Torsten | -- |
| Walton, Alan | -- |
| Gray, Mary | -- |
| Borer, Michael | -- |
| Brege, Laura | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Iversen, Leslie | 0 | 0 |
| Hacksell, Uli | 424,084 | 3,093,980 |
| Aasen, Thomas | 199,000 | 1,533,340 |
| Mills, Roger | 0 | 0 |
| Kaplan, Lester | 0 | 0 |
| Rasmussen, Torsten | 0 | 0 |
| Walton, Alan | 0 | 0 |
| Gray, Mary | 0 | 0 |
| Borer, Michael | 0 | 0 |
| Brege, Laura | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| TOLF BO RAGNAR | 10,000 | $1.08 |
| TOLF BO RAGNAR | 10,000 | $1.08 |
| IVERSEN LESLIE L | 3,000 | $1.65 |
| IVERSEN LESLIE L | 1,000 | $0.00 |
| IVERSEN LESLIE L | 1,000 | $0.00 |
| HACKSELL ULI | 10,000 | $1.60 |
| HACKSELL ULI | 10,000 | $0.00 |
| HACKSELL ULI | 10,000 | $0.00 |
| RASMUSSEN TORSTEN | 1,000 | $1.20 |
| RASMUSSEN TORSTEN | 1,000 | $1.80 |
| RASMUSSEN TORSTEN | 1,000 | $4.00 |
| RASMUSSEN TORSTEN | 1,000 | $1.80 |
| AASEN THOMAS H | 5,000 | $1.08 |
| AASEN THOMAS H | 8,000 | $0.00 |
| AASEN THOMAS H | 2,000 | $10.90 |
| AASEN THOMAS H | 4,000 | $10.75 |
| AASEN THOMAS H | 8,000 | $1.08 |
| AASEN THOMAS H | 8,000 | $0.00 |
| AASEN THOMAS H | 2,000 | $10.94 |
| IVERSEN LESLIE L | 1,000 | $1.20 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
